Nearly eight years after securing a historic first approval for a spinal muscular atrophy drug, Biogen is seeking to launch a ...
Sage Therapeutics is reeling from another mid-stage setback as its investigational medicine dalzanemdor has missed the mark ...
As Merck builds out its immunology research lab in London, it's partnering with a local biotech startup that has remained ...
As it works to rebuild from an earlier gene therapy setback, Astellas is doubling down on the one-and-done modality in a new ...
Scholar Rock seeks $275M in stock sale: After announcing the success of a pivotal clinical trial for its muscle-targeted spinal muscular atrophy treatment, Scholar Rock’s shares $SRRK skyrocketed over ...
Last October was an FDA approval. This October is a $68 million fundraising round. Next year, maybe a drug launch.
Liquidia’s stock $LQDA rose about 10% on Monday following a win in the US Supreme Court for its treprostinil inhalation ...
Novo Nordisk and Mylan Pharmaceuticals, now part of Viatris, have settled their patent dispute over Novo’s blockbuster ...
Scholar Rock announced its experimental add-on treatment for spinal muscular atrophy significantly improved motor function ...
AstraZeneca is strengthening its cardiovascular disease pipeline with a $100 million upfront deal for a lipid-targeting drug ...
The news that Pfizer has an activist isn’t a surprise. For the last few months at Endpoints News, we’ve been asking which ...
A three-year-old startup based on decades of research in cell depletion is betting that some of the hottest tools in oncology may work even better in other diseases. Arda Therapeutics has raised a $43 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback